ACETO Corp's subsidiary to launch Ultramicrosize Griseofluvin tablets

By Admin
ACETO Corporation's finished dosage form generics subsidiary namely Rising Pharmaceuticals Inc will be launching the first generic version of the 1...

ACETO Corporation's  finished dosage form generics subsidiary namely Rising Pharmaceuticals Inc will be launching the first generic version of the 125mg and 250mg strengths of Ultramicrosize Griseofluvin tablets USP.

These tablets are the FDA approved generic version of PEDiNOL Pharmacal Inc’s Gris-PEG®. According to the IMS Health Data, the U.S. market sales for ultramicrosize Griseofluvin tablets, that is antifungal antibiotic that fights infections caused by fungus, was approximately $16.7 million for 12 months ended June 30, 2012.

ACETO Corporation is a global leader in the marketing, sale and distribution of products for human health, pharmaceutical ingredients and performance chemicals.

With business operations in nine countries, ACETO distributes more than 1,100 chemical compounds used as finished products or raw materials in the nutraceutical, pharmaceutical, coatings, agricultural, and industrial chemical industries. Its global operations includes a staff of 26 in China and 12 in India, are distinctive in the industry and enables its worldwide sourcing and regulatory capabilities. 

Rising Pharmaceuticals is engaged in marketing and distributing innovative branded and multi-source prescription and over-the-counter pharmaceutical products. Its products are manufactured in state-of-the-art GMP facilities using quality assurance techniques that meet regulatory standards. 

The company shares its own distribution channel analysis and marketing innovation and also dedicates itself to supporting its partners’ existing marketing programs.


Featured Articles

From Ukraine to Myanmar, reports reveal attacks on hospitals

Reports from the Centre for Information Resilience shows Russian army attacked Ukrainian hospitals & Myanmar’s military Junta targeted medical facilities

The use of AI in biopharma according to L.E.K. Consulting

L.E.K. Consulting’s Stephen Roper & Anne Dhulesia discuss the use of AI in biopharma and unleashing the power of Big Data in the healthcare sector

Novartis Kisqali minimises breast cancer recurrence

The use of ET therapy and Novartis Kisqali lowers the risk of breast cancer recurrence, while helping patients maintain a positive quality of life

Rimidi CEO Lucienne Marie Ide on improving patient outcomes


WatchGuard Technologies & cybersecurity in healthcare


FluidAI & Medtronic work on remote patient monitors

Technology & AI